Overview
At GeneSynth Innovations, we are at the forefront of creating innovative genetic therapies that address unmet medical needs in rare diseases. With significant advancements in gene editing and synthetic biology, our mission is to revolutionize treatment options for patients worldwide. The foundation of our startup was laid in late 2024, when we successfully developed our first prototype for a genetic delivery system that enhances the efficiency and safety of gene therapies. Since then, we have made remarkable progress, securing initial funding of $250,000 from angel investors, and completing preclinical trials with promising results. Our technology stands out due to its unique delivery mechanism, which has demonstrated a 30% improvement in gene expression over traditional methods. We have also established partnerships with leading universities for further research and validation. Now, as we look to commercialize our product, we are seeking an investment of $69,000. This capital will enable us to transition from a research-focused organization to a fully operational entity capable of conducting clinical trials and scaling production. With a rapidly growing market for genetic therapie…
Use of funds
The funds from this investment will be allocated as follows:
- Hiring of specialized personnel: $30,000
- Enhancement of laboratory and production facilities: $25,000
- Initial marketing and regulatory compliance: $14,000
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.